Reviva Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:RVPH)

by · The Markets Daily

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH – Get Free Report) was the recipient of unusually large options trading on Wednesday. Stock traders acquired 25,745 call options on the company. This represents an increase of 295% compared to the typical volume of 6,521 call options.

Reviva Pharmaceuticals Trading Down 11.6%

RVPH stock opened at $0.28 on Thursday. Reviva Pharmaceuticals has a one year low of $0.25 and a one year high of $2.17. The firm has a 50-day moving average of $0.56 and a two-hundred day moving average of $0.52. The firm has a market capitalization of $32.68 million, a PE ratio of -0.62 and a beta of -0.02.

Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.05. On average, equities research analysts anticipate that Reviva Pharmaceuticals will post -0.97 earnings per share for the current year.

Analysts Set New Price Targets

RVPH has been the subject of several research analyst reports. Chardan Capital upgraded Reviva Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, November 19th. HC Wainwright reiterated a “buy” rating and issued a $4.00 price target on shares of Reviva Pharmaceuticals in a research report on Tuesday. Weiss Ratings restated a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of Reviva Pharmaceuticals to a “sell” rating in a report on Saturday, October 4th. Finally, Benchmark cut their target price on shares of Reviva Pharmaceuticals from $14.00 to $7.00 and set a “speculative buy” rating for the company in a research note on Monday, September 15th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $3.86.

Read Our Latest Stock Analysis on Reviva Pharmaceuticals

Trending Headlines about Reviva Pharmaceuticals

Here are the key news stories impacting Reviva Pharmaceuticals this week:

  • Positive Sentiment: Analyst bullishness — HC Wainwright reaffirmed a “buy” rating and set a $4.00 price target, implying large upside versus the current price; this bullish call likely fuels speculative interest. Read More.
  • Positive Sentiment: Additional buy reiteration — D. Boral Capital maintained a “buy” rating with a $2.00 target, another institutional endorsement that can support upside momentum. Read More.
  • Positive Sentiment: Heavy call option buying — traders purchased large volumes of call options (roughly 25,745 calls, ~295% above typical volume), which indicates speculative bullish positioning that can amplify intraday price moves. Read More.
  • Neutral Sentiment: Short-interest data flagged as zero/incomplete — reported short interest shows 0 shares (data appears unreliable/NaN change), so it provides no clear signal on short-seller positioning. No meaningful short-squeeze implication from this report.
  • Negative Sentiment: Regulatory setback — the FDA recommended a second Phase 3 trial for brilaroxazine in schizophrenia after a pre-NDA meeting, meaning more time, data and cost before potential approval; this is the primary driver of the stock decline. Read More.
  • Negative Sentiment: Funding and dilution risk — analysts (Roth) warn Reviva may need an additional $60M–$75M to complete the schizophrenia study, raising dilution and financing concerns that weigh on valuation. Read More.
  • Negative Sentiment: Price-target cuts and market reaction — Roth lowered its price target to $1.50 (from $3), and coverage/ headlines note a sharp intraday plunge after the FDA news, reinforcing negative sentiment and selling pressure. Read More. Read More.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of RVPH. Armistice Capital LLC bought a new stake in shares of Reviva Pharmaceuticals in the 2nd quarter valued at approximately $1,026,000. 683 Capital Management LLC bought a new stake in Reviva Pharmaceuticals in the second quarter worth approximately $381,000. Persistent Asset Partners Ltd increased its stake in shares of Reviva Pharmaceuticals by 300.0% during the 2nd quarter. Persistent Asset Partners Ltd now owns 641,174 shares of the company’s stock worth $244,000 after purchasing an additional 480,864 shares during the last quarter. Millennium Management LLC raised its holdings in shares of Reviva Pharmaceuticals by 15.0% during the 3rd quarter. Millennium Management LLC now owns 1,711,221 shares of the company’s stock valued at $631,000 after purchasing an additional 223,178 shares in the last quarter. Finally, Lido Advisors LLC bought a new position in shares of Reviva Pharmaceuticals during the 3rd quarter valued at $37,000. Hedge funds and other institutional investors own 63.18% of the company’s stock.

About Reviva Pharmaceuticals

(Get Free Report)

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.

Featured Articles